Armata Pharmaceuticals, Inc. (ARMP) News
Follow Armata Pharmaceuticals, Inc. (ARMP) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Armata Reports $54.9M Q3 Net Income on $69.6M Loan Fair-Value Gain
Armata reported Q3 2026 net income of $54.9 million, compared with a $26.7 million net loss in Q3 2025. The result was primarily driven by a $69.6 million convertible-loan fair-value gain. Its planned AP-SA02 Phase 3 stu
EARNINGS | Nov 12, 2026, 09:05 PM UTC
L
HC Wainwright & Co. reiterates Buy rating on Armata Pharmaceuticals, $15 price target
HC Wainwright & Co. reiterated their Buy rating on Armata Pharmaceuticals's stock with a price target of $15.00.The price target implies an upside of 257.1% from the Sep 22 close of $4.20.Key takeaways from the analyst n
EQUITY | Sep 23, 2026, 03:04 PM UTC
L
Armata Gets $3.7M in Additional Funding From Defense Dept. for Bacterial Infection Treatment
By Kelly CloonanArmata Pharmaceuticals said it received an additional $3.7 million in non-dilutive funds from the Defense Department to continue developing a treatment for a type of bacterial infection.The biotechnology
NEWS | Sep 23, 2026, 11:46 AM UTC
H
Armata Pharmaceuticals receives $3.7M in DoW funding to support AP-SA02 Phase 3
Armata Pharmaceuticals received $3.7 million in additional non-dilutive funding from the U.S. Department of War to support Phase 3 development of AP-SA02.Key Highlights:Original SEC Filing: Armata Pharmaceuticals, Inc. [
GEOPOLITICS | Sep 23, 2026, 11:14 AM UTC
H
Armata Pharmaceuticals Receives Additional $3.7M In Non-dilutive Funds From US Department Of War For Phase 3 Development Program For AP-SA02
Importantly, the $3.7 million represents the first funding received specifically for Phase 3 execution pursuant to a previously announced DoW award, received through the Medical Technology Enterprise Consortium ("MTEC")
LIVE | Sep 23, 2026, 11:09 AM UTC
H
ARMP - Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
ARMP - Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
GEOPOLITICS | Sep 23, 2026, 11:00 AM UTC
L
ARMP - Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates
ARMP - Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates
NEWS | Sep 21, 2026, 11:00 AM UTC
L
ARMP - Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
ARMP - Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
EQUITY | Sep 10, 2026, 11:00 AM UTC
L
ARMP - Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generati
ARMP - Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
EQUITY | Sep 03, 2026, 11:01 AM UTC
L
ARMP Announces Q2 2026 Financial Results
ARMP announces financial results for the second quarter 2026 and provides a corporate update
EARNINGS | Aug 12, 2026, 08:06 PM UTC
L
Armata Pharma Reaches FDA Agreement on Pediatric Study Plan for AP-SA02
() -- Armata Pharmaceuticals (ARMP) said Monday it has reached agreement with the US Food and Drug Administration on an agreed initial pediatric study plan for AP-SA02, clearing a regulatory requirement ahead of a potent
REGULATION | Jul 13, 2026, 11:47 AM UTC
L
Armata Pharmaceuticals reaches agreement with FDA on iPSP for AP-SA02
Armata Pharmaceuticals...
EQUITY | Jul 13, 2026, 11:04 AM UTC
M
ARMP Receives $2.5M Funding
Armata Pharmaceuticals receives $2.5 million in non-dilutive award funding from the U.S. Department of Defense to support AP-SA02
EQUITY | Jun 23, 2026, 11:03 AM UTC